2025-04-23 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**0. Key Figures Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The cumulative return of MRK significantly lags behind the S&P 500 (VOO).  Recent price action shows MRK trading below its key moving averages, suggesting potential downside.  Technical indicators (RSI and PPO) point towards bearish momentum.  Profitability remains strong but recent earnings show some variability.


**1. Performance Comparison:**

* **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a broad range of healthcare products.

* **Cumulative Return:**
    * MRK: 22.75%
    * VOO (S&P 500): 76.31%
    * Return Difference: -53.56%  (MRK underperformed VOO significantly)
    * Relative Divergence: 25.0% (This means MRK's underperformance relative to VOO is in the 25th percentile of its historical range, suggesting a relatively less extreme underperformance compared to its historical context.)


* **Alpha and Beta Analysis:**  The provided data shows fluctuating Alpha and Beta values across the years, indicating varying levels of risk and outperformance relative to the market.  Note that a negative Alpha suggests underperformance.  Higher Beta values (above 1) indicate higher volatility relative to the market.  Market capitalization (Cap(B)) shows consistent growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 58.6% | -22.0% | 0.1 | 108.6 |
| 2016-2018  | 49.0% | 66.4% | 27.0% | 0.4 | 151.9 |
| 2017-2019  | 48.0% | 66.4% | 14.0% | 0.9 | 185.8 |
| 2018-2020  | 26.0% | 66.4% | -4.0% | 0.7 | 172.4 |
| 2019-2021  | 4.0% | 65.6% | -56.0% | 0.5 | 175.4 |
| 2020-2022  | 20.0% | 69.3% | 11.0% | 0.5 | 262.1 |
| 2021-2023  | 43.0% | 69.3% | 22.0% | 0.3 | 264.8 |
| 2022-2024  | -3.0% | 69.3% | -24.0% | 0.2 | 248.2 |
| 2023-2025  | -47.0% | 70.2% | -61.0% | 0.2 | 198.7 |


**2. Recent Price Movement:**

* Closing Price: $78.97
* 5-Day Moving Average: $77.93
* 20-Day Moving Average: $82.59
* 60-Day Moving Average: $88.38

The price is below all three moving averages, a bearish signal.  The recent price increase (from $77.85) is relatively modest and hasn't yet broken above the key moving averages.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.435 (Medium Risk)
* **RSI:** 32.01 (Below 30, indicating oversold conditions, but not necessarily a strong buy signal alone)
* **PPO:** -0.33 (Negative, suggesting bearish momentum)
* **Recent Relative Strength Change (20-day):** +2.4 (Short-term upward trend, but within a larger downward trend)
* **Price Change:** A 1.44 increase is a relatively small positive move, not indicative of a significant 'rebound' or 'sudden drop'.
* **Expected Return (2+ years):** -11.6% (Expected underperformance relative to the S&P 500 over the long term)


**4. Recent Earnings Analysis:**

The provided earnings data shows some variability in EPS and revenue, with fluctuations across quarters.  No clear trend is immediately apparent.  Further analysis would be needed to determine underlying drivers of this variation.  Note there appears to be duplicate data entry for 2024-11-06.

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      |


**5. Financial Information:**

Both revenue and profitability (profit margin) show relatively stable, strong performance throughout the reported quarters, although there are some minor fluctuations.  Equity and Return on Equity (ROE) figures indicate growth in capital but fluctuating profitability;  a negative ROE in 2023-12-31 is notable.


| Quarter     | Revenue     | Profit Margin | Equity      | ROE     |
|-------------|-------------|---------------|-------------|---------|
| 2024-12-31  | $15.62B     | 75.50%        | $46.31B     | 8.08%   |
| 2024-09-30  | $16.66B     | 75.51%        | $44.50B     | 7.09%   |
| 2024-06-30  | $16.11B     | 76.76%        | $43.58B     | 12.52%  |
| 2024-03-31  | $15.78B     | 77.56%        | $40.36B     | 11.80%  |
| 2023-12-31  | $14.63B     | 73.26%        | $37.58B     | -3.26%  |



**6. Overall Analysis:**

Merck (MRK) currently shows significant underperformance relative to the S&P 500,  a bearish technical outlook (based on moving averages, RSI, and PPO), and a projected negative return compared to the market index.  While the company's financial fundamentals (revenue, profit margin) appear relatively healthy,  the negative expected return and the variability in earnings and ROE raise concerns.  Investors should carefully consider the risks before investing,  especially given the projected long-term underperformance. Further investigation into the drivers behind the fluctuations in earnings and ROE is recommended.  This analysis is based solely on the provided data and does not constitute financial advice.
